|
Synonyms: ADS-001 | ADS001 | ARO-AAT
Compound class:
Nucleic acid
Comment: Fazirsiran (ADS-001) is a small interfering RNA (siRNA) that is designed to target the mRNA that would otherwise be translated into a mutant, misfolded and aggregating version of the AAT protein (known as Z-AAT which is transcribed from the mutant SERPINA1 PI*ZZ allele) in patients with alpha-1 antitrypsin deficiency [2-4].
To improve pharmacokinetics, the nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone, and it has sugar modifications at both ends of the forward strand to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs). |
Classification ![]() |
|
| Compound class | Nucleic acid |
| Compound subclass | siRNA |
| Target | Z-AAT mRNA |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11949 | fazirsiran |
Synonyms ![]() |
| ADS-001 | ADS001 | ARO-AAT |
Database Links ![]() |
|
| CAS Registry No. | 2175009-08-0 (source: WHO INN record) |
| DrugBank Ligand | DB17891 |
| Search PubMed clinical trials | fazirsiran |
| Search PubMed titles | fazirsiran |
| Search PubMed titles/abstracts | fazirsiran |